Page last updated: 2024-08-22

camptothecin and efatutazone

camptothecin has been researched along with efatutazone in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hyodo, I; Komatsu, Y; Machida, N; Ohtsu, A; Onuma, H; Sasaki, T; Yachi, Y; Yamazaki, K; Yoshino, T; Yuki, S	1

Trials

1 trial(s) available for camptothecin and efatutazone

Article	Year
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Investigational new drugs, 2014, Volume: 32, Issue:3 Topics: Adiponectin; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; PPAR gamma; Thiazolidinediones; Treatment Outcome	2014

Article

Year

Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

Investigational new drugs, 2014, Volume: 32, Issue:3

Topics: Adiponectin; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; PPAR gamma; Thiazolidinediones; Treatment Outcome

2014